| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/30/2009 | WO2009055002A1 Combined inhibitors of cyclooxygenase and semicarbazide-sensitive amine oxidase (ssao) (vascular adhesion protein, vap-1) |
| 04/30/2009 | WO2009055001A2 Methods of treating aging and methods of screening candidate agents therefor |
| 04/30/2009 | WO2009054992A1 Antimicrobial compositions comprising docusate |
| 04/30/2009 | WO2009054984A1 Heterocycle phenyl amide t-type calcium channel antagonists |
| 04/30/2009 | WO2009054982A1 Pyrazinyl amide t-type calcium channel antagonists |
| 04/30/2009 | WO2009054970A1 Mesylate salt of an ikk inhibitor |
| 04/30/2009 | WO2009054952A2 Small molecule inhibitors of parp activity |
| 04/30/2009 | WO2009054941A1 Therapeutic compounds |
| 04/30/2009 | WO2009054935A1 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy |
| 04/30/2009 | WO2009054923A2 Synthesis and crystalline forms of cb-1 antagonist/inverse agonist |
| 04/30/2009 | WO2009054922A1 Dna sequencing with non-fluorescent nucleotide reversible terminators and cleavable label modified nucleotide terminators |
| 04/30/2009 | WO2009054916A2 Oligomer conjugates of lidocaine and its derivatives |
| 04/30/2009 | WO2009054914A1 Compositions and methods for treatment of diabetic retinopathy |
| 04/30/2009 | WO2009054878A2 Compositions and methods for the treatment of neoplasia |
| 04/30/2009 | WO2009054864A1 Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| 04/30/2009 | WO2009054845A1 Apparatus and methods using ultrasonically energized polymers for topical pain relief |
| 04/30/2009 | WO2009054813A1 Method of delivering an anti-cancer agent to a cell |
| 04/30/2009 | WO2009054794A1 Amino 1,2,4-triazole derivatives as modulators of mglur5 |
| 04/30/2009 | WO2009054793A1 Thiophene 1,2,4-triazole derivatives as modulators of mglur5 |
| 04/30/2009 | WO2009054792A1 Aminopyridine derivatives as modulators of mglur5 |
| 04/30/2009 | WO2009054791A1 Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5 |
| 04/30/2009 | WO2009054790A1 Amide linked heteroaromatic derivatives as modulators of mglur5 |
| 04/30/2009 | WO2009054789A1 1,2,3-triazole pyrrolidine derivatives as modulators of mglur5 |
| 04/30/2009 | WO2009054787A1 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5 |
| 04/30/2009 | WO2009054786A1 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5 |
| 04/30/2009 | WO2009054785A1 1,2,4-triazole ether derivatives as modulators of mglur5 |
| 04/30/2009 | WO2009054725A2 Means and methods for counteracting muscle disorders |
| 04/30/2009 | WO2009054550A1 Nifedipine-containing press coated tablet and method of preparing the same |
| 04/30/2009 | WO2009054544A1 Ampa receptor antagonists for parkinson's disease and movement disorders |
| 04/30/2009 | WO2009054543A1 Ampa receptor antagonists and zonisamide for parkinson's disease and movement disorders |
| 04/30/2009 | WO2009054479A1 Spiro-ring compound and use thereof for medical purposes |
| 04/30/2009 | WO2009054468A1 Azolecarboxamide compound or salt thereof |
| 04/30/2009 | WO2009054463A1 Pharmaceutical composition containing lipophilic il-2 production inhibitor |
| 04/30/2009 | WO2009054458A1 Composition for reducing the level of glucose, malondialdehyde-modified ldl, homocysteine and/or c-reactive protein in blood |
| 04/30/2009 | WO2009054454A1 Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient |
| 04/30/2009 | WO2009054439A1 Pai-1 production inhibitor |
| 04/30/2009 | WO2009054434A1 Amine derivative having npy y5 receptor antagonist activity and use thereof |
| 04/30/2009 | WO2009054432A1 Intraorally rapidly disintegrating pharmaceutical composition, and method for production thereof |
| 04/30/2009 | WO2009054423A1 Oxadiazolidinedione compound |
| 04/30/2009 | WO2009054401A1 Anti-viral agent comprising heterocyclic aromatic compound as active ingredient |
| 04/30/2009 | WO2009054390A1 Thiazolidinedione compound |
| 04/30/2009 | WO2009054360A1 Agent for specifically reducing visceral fat |
| 04/30/2009 | WO2009054332A1 Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| 04/30/2009 | WO2009054181A1 Composition for treatment of joint disease |
| 04/30/2009 | WO2009054150A1 Tetrapyrrole derivative, and use thereof for medical purposes |
| 04/30/2009 | WO2009054007A1 Antiemetic-oral contraceptive combination |
| 04/30/2009 | WO2009054001A1 A pharmaceutical composition and a process thereof |
| 04/30/2009 | WO2009053997A1 Amino arylsulfonamide compounds and their use as 5-ht6 ligands |
| 04/30/2009 | WO2009053994A1 Process for preparing pure amorphous quinapril hydrochloride |
| 04/30/2009 | WO2009053932A1 Methods for improving female sexual function |
| 04/30/2009 | WO2009053895A2 Quinoline urotensin-ii receptor antagonists |
| 04/30/2009 | WO2009053842A2 Prevention of recurrence of urethral stricture after a conventional treatment |
| 04/30/2009 | WO2009053824A1 Lipoic acid pellet composition |
| 04/30/2009 | WO2009053804A2 Idarubicin for the treatment of lymphoma in a dog |
| 04/30/2009 | WO2009053802A1 Functional drink |
| 04/30/2009 | WO2009053799A1 Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| 04/30/2009 | WO2009053794A2 The use of a monocyclic monoterpene in manufacturing medicaments for treatment of diabetes |
| 04/30/2009 | WO2009053763A1 New non-peptide derivatives as bradykinin b1 antagonists |
| 04/30/2009 | WO2009053758A1 Anti-malarial pharmaceutical composition |
| 04/30/2009 | WO2009053754A2 Novel crystalline forms |
| 04/30/2009 | WO2009053750A2 Novel crystalline and amorphous forms |
| 04/30/2009 | WO2009053748A2 Novel crystalline forms |
| 04/30/2009 | WO2009053733A2 Novel crystalline forms |
| 04/30/2009 | WO2009053732A1 Novel salt |
| 04/30/2009 | WO2009053731A1 Process for preparing o-desmethylvenlafaxine |
| 04/30/2009 | WO2009053716A1 Purine derivatives useful as pi3 kinase inhibitors |
| 04/30/2009 | WO2009053715A1 Thienopyrimidiene derivatives as pi3k inhibitors |
| 04/30/2009 | WO2009053697A1 Polymorphic forms of ( s ) -rotigotine hydrochloride |
| 04/30/2009 | WO2009053694A1 Therapeutic oxy-phenyl-aryl compounds and their use |
| 04/30/2009 | WO2009053683A2 Treatment of inflammatory diseases |
| 04/30/2009 | WO2009053654A2 Gemcitabine phosphoester prodrugs as anticancer agents |
| 04/30/2009 | WO2009053628A2 Novel compounds, preparation and uses thereof |
| 04/30/2009 | WO2009053601A2 Method for preparing a vaccine composition comprising at least one antigen and at least one adjuvant |
| 04/30/2009 | WO2009053553A1 Rimonabant 2-methoxyethanol solvate and method for preparing same |
| 04/30/2009 | WO2009053552A1 Rimonabant methanol solvate, method for preparing same and pharmaceutical compositions containing same |
| 04/30/2009 | WO2009053551A1 Rimonabant n,n-dimethylformamide solvate, and method for preparing same |
| 04/30/2009 | WO2009053550A1 Rimonabant n-methylpyrrolidone solvate, method for preparing same and pharmaceutical compositions containing same |
| 04/30/2009 | WO2009053549A1 Rimonabant dmso solvate, method for preparing same and pharmaceutical compositions containing same |
| 04/30/2009 | WO2009053548A1 Rimonabant 1,4-dioxane solvate, method for preparing same and pharmaceutical compositions containing same |
| 04/30/2009 | WO2009053466A1 Long acting injectable formulations |
| 04/30/2009 | WO2009053459A1 4-benz0yl-1-substituted-piperazin-2-0ne derivatives as p2x7 modulators |
| 04/30/2009 | WO2009053452A1 4,4-disubstituted piperidines |
| 04/30/2009 | WO2009053449A1 Thiazoles which potentiate ampa receptor and medicinal uses thereof |
| 04/30/2009 | WO2009053448A1 Compounds which potentiate ampa receptor and uses thereof in medicine |
| 04/30/2009 | WO2009053446A2 Pregabalin intermediates and process for preparing them and pregabalin |
| 04/30/2009 | WO2009053444A1 Compounds of 2,3-dihydro-benzofuran |
| 04/30/2009 | WO2009053443A2 Indane compounds |
| 04/30/2009 | WO2009053441A1 Phenylpyrrolidine compounds |
| 04/30/2009 | WO2009053440A1 Indoline compounds |
| 04/30/2009 | WO2009053439A2 An amorphous form of an anti-inflammatory compound |
| 04/30/2009 | WO2009053424A1 Crystalline salt of montelukast |
| 04/30/2009 | WO2009053373A1 Quinolinone derivatives as parp inhibitors |
| 04/30/2009 | WO2009053277A1 Aspartyl protease inhibitors |
| 04/30/2009 | WO2009053269A1 Novel kinase inhibitors |
| 04/30/2009 | WO2009053268A1 Novel phenyl-substituted piperazino-dihydrothienopyrimidines |
| 04/30/2009 | WO2009053259A1 Process for the production of telithromycin |
| 04/30/2009 | WO2009053102A1 Novel imidazole derivatives |
| 04/30/2009 | WO2009053101A1 Novel imidazole derivatives |
| 04/30/2009 | WO2009053070A1 Compounds for treating demyelination conditions |
| 04/30/2009 | WO2009053038A2 Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor |